Memorial Sloan Kettering Cancer Center
ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan Doubles PFS in MBC With Low HER2 Expression
By
ecancer
FEATURING
Shanu Modi
By
ecancer
FEATURING
Shanu Modi
Login to view comments.
Click here to Login